Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 26:2018:2340389.
doi: 10.1155/2018/2340389. eCollection 2018.

Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms

Panpan Zhang  1 , Jiangyuan Yu  2 , Jie Li  1 , Lin Shen  1 , Nan Li  2 , Hua Zhu  2 , Shizhen Zhai  2 , Yan Zhang  2 , Zhi Yang  2 , Ming Lu  1
Affiliations

Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms

Panpan Zhang et al. Contrast Media Mol Imaging. .

Abstract

Background: To evaluate the clinical and prognostic value of PET/CT with combination of 68Ga-DOTATATE and 18F-FDG in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).

Method: 83 patients of GEP-NENs who underwent 68Ga-DOTATATE and 18F-FDG PET/CT were enrolled between June 2013 and December 2016. Well-differentiated (WD) NETs are divided into group A (Ki-67 < 10%) and group B (Ki-67 ≥ 10%), and poorly differentiated (PD) NECs are defined as group C. The relationship between PET/CT results and clinicopathological characteristics was retrospectively investigated.

Result: For groups A/B/C, the sensitivities of 68Ga-DOTATATE and 18F-FDG were 78.8%/83.3%/37.5% and 52.0%/72.2%/100.0%. A negative correlation between Ki-67 and SUVmax of 68Ga-DOTATATE (R = -0.415; P ≤ 0.001) was observed, while a positive correlation was noted between Ki-67 and SUVmax of 18F-FDG (R = 0.683; P ≤ 0.001). 62.5% (5/8) of patients showed significantly more lesions in the bone if 68Ga-DOTATATE was used, and 22.7% (5/22) of patients showed more lymph node metastases if 18F-FDG was used.

Conclusions: The sensitivity of dual tracers was correlated with cell differentiation, and a correlation between Ki-67 and both SUVmax of PET-CTs could be observed. 68Ga-DOTATATE is suggested for WD-NET and 18F-FDG is probably suitable for patients with Ki-67 ≥ 10%.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of SUVmax of PET/CT according to primary sites ((a) and (b)) and tumor grade ((c) and (d)). The sensitivity of group A (G1 + G2a = Ki-67 < 10%), group B (G2b + G3a = well-differentiated neoplasms with Ki-67 ≥ 10%), and group C (G3b = poorly differentiated neoplasms with Ki-67 > 20%) in PET/CT imaging.
Figure 2
Figure 2
A 37-year-old women with pancreatic NEC G3 (Ki-67 = 80%) and lymph node, liver, and bone metastases, from whom the primary lesion has been resected. 18F-FDG PET/CT showed more liver lesions, while 68Ga-DOTATATE detected more bone lesions. ((A) and (a)) Liver lesions showed heterogeneity in SSTR expression. ((B) and (b) and (C) and (c)) 18F-FDG PET/CT failed to show bone metastases in rib and lumbar vertebra.
Figure 3
Figure 3
The overall survival of unresectable patients detected with dual tracers: (a) Kaplan-Meier survival curve for unresectable patients, (A) positive for both tracers, (B) 68Ga-DOTA-TATE only, and (C) 18F-FDG only; (b) unresectable NET patients with 68Ga-DOTA-TATE results (positive or negative); (c) unresectable NET patients with 18F-FDG results (positive or negative); (d) unresectable NEC patients with 68Ga-DOTA-TATE results (positive or negative).
Figure 4
Figure 4
PET/CT imaging and treatment regime.
See this image and copyright information in PMC

References

    1. Garcia-Carbonero R., Capdevila J., Crespo-Herrero G., et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the national cancer registry of Spain (RGETNE) Annals of Oncology. 2010;21(9):1794–1803. doi: 10.1093/annonc/mdq022. - DOI - PubMed
    1. Klimstra D. S., Modlin I. R., Adsay N. V., et al. Pathology reporting of neuroendocrine tumors: Application of the delphic consensus process to the development of a minimum pathology data set. The American Journal of Surgical Pathology. 2010;34(3):300–313. doi: 10.1097/PAS.0b013e3181ce1447. - DOI - PubMed
    1. Carlinfante G., Baccarini P., Berretti D., et al. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: A comparative cytohistological study of 53 cases. Virchows Archiv. 2014;465(1):49–55. doi: 10.1007/s00428-014-1585-7. - DOI - PubMed
    1. Rindi G., Klöppel G., Couvelard A., et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Archiv. 2007;451(4):757–762. doi: 10.1007/s00428-007-0452-1. - DOI - PubMed
    1. Yao J. C., Phan A. T., Chang D. Z., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology. 2008;26(26):4311–4318. doi: 10.1200/jco.2008.16.7858. - DOI - PMC - PubMed

MeSH terms

Supplementary concepts